Cargando…
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.
Four monoclonal antibodies (MAbs) specific for the extracellular domain of the human erbB-2/HER2 protein (FRP5, FSP16, FWP51 and FSP77) have been isolated (Harwerth et al., J. Biol. Chem., 267, 15160-15167, 1992). In this paper we describe the effects of erbB-2 specific MAb administration on the tum...
Autores principales: | Harwerth, I. M., Wels, W., Schlegel, J., Müller, M., Hynes, N. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968669/ https://www.ncbi.nlm.nih.gov/pubmed/7903153 |
Ejemplares similares
-
A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016) -
In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.
por: Tokuda, Y., et al.
Publicado: (1996) -
Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo
por: Lahlou, Hicham, et al.
Publicado: (2012) -
The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003) -
Human Tumor Growth Suppression by Apoptosis Induced with Anti‐ErbB‐2 Chimeric Monoclonal Antibody
por: Sasaki, Shigeru, et al.
Publicado: (1998)